Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
One year into the coronavirus disease 2019 (COVID-19) pandemic, the African continent still seems to be spared from the devastating effects the disease had in other continents. Africa’s COVID-19 seems to be of a milder nature both in adults and children. However, lack of data from Africa is significant, and more studies are needed to validate the disease status, clinical manifestations, and future implications for Africa. In this study, we report pediatric COVID-19 features in Africa represented by 8 countries.

We conducted a systematic literature review (March 2020 to November 2021) using the terms COVID-19 Africa, COVID-19 Africa Pediatrics, and COVID-19 Africa Children. Case characteristics (10 studies in 8 countries, 294 patients positive for severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] by polymerase chain reaction; Table 1, Supplementary Table 1) are described. Symptoms and comorbidities were combined, compared, and analyzed by weighted analysis methods. SPSS version 26 was used for this analysis.

Ethiopian patients were the oldest. The mean age of our cohort was 11.4 years with a minimum of 5.75 years and a maximum of 15 years. Patients from Ethiopia (Table 1, Supplementary Figure 1) were on average 15 years old followed by Morocco, at 13 years old. The youngest patients were from Sierra Leone, at 5.75 years old. Female patients made 55% of our cohort, but gender distribution was not uniform. The Tunisian cohort was 87.5% males, whereas the South African cohort was 73.9% females. No deaths were reported in the overall cohort.

Fever was the most common symptom, found in 24.6% of the cohort. Its distribution was 19.9% in the Moroccan cohort, 5.6% in Ethiopia, and up to 100% in South African and Tunisian cohorts. Cough was present in 20% of our African cohort, ranging from 2.2% in Sierra Leone to 22.5% in the Nigerian cohort. Dyspnea was present in 8.5% (25% in Cameroon cohort) and myalgia in 60.8%. Interestingly, there were 63% asymptomatic cases. The Egyptian cohort had 100% asymptomatic cases, whereas Nigeria and Sierra Leone reported 33% and 22%, respectively.

Diarrhea and abdominal pain were frequent. Our cohort had an 18.4% diarrhea prevalence, with the highest prevalence in Tunisia (87.5%) and the lowest in Morocco (6.7%). Abdominal pain was present in 16.7%, with a prevalence of 100% in Tunisia and 1.3% in Morocco. Nausea was present in 8% and vomiting in 4.9%. Nausea was noted in 50% in the Tunisian cohort, whereas 4.4% and 5.7% had vomiting in Ethiopia and Nigeria, respectively. The least common symptom was anosmia at 4.3%, with the highest prevalence of 5.8% in Morocco (Table 1, Supplementary Figure 2).

Studies from South Africa and Tunisia had more reported symptoms, some of which were highly prevalent. Cumulatively, conjunctivitis was present in 64.5% of these 2 countries’ cohorts. More specifically, it was reported in 65.2% in South Africa and 62.5% in Tunisia. Rash followed a similar profile, although at much higher cumulative prevalence of 87.1%, with 87% for South Africa and 87.5% for Tunisia.

Although HIV and Ebola virus had major damaging effects in Africa, SARS-CoV-2 seems to have a different profile. Indeed, more than 60% of African children with COVID-19 were asymptomatic; this is in contrast to what has been reported in an Alberta, Canada study with 33% asymptomatic cases. Compulsory viral vaccinations given routinely in early childhood in Africa might be partially providing some level of resistance against SARS-CoV-2 infections. Angiotensin-converting enzyme 2 gene expression in the nasal epithelium is highest in younger children and decreases with age. This is likely a reason why pediatric cases in general and those in our study did not display significant respiratory symptoms, because the virus might have been mitigated by the pediatric immune system before reaching the lungs.

A comparison of our African cohort with a US cohort of 6581 pediatric cases revealed different profiles with fever at 24.6% vs 48%, cough at 20% vs 37.6%, and vomiting at 4.9% vs 13.2% in African vs US cases, respectively. These profiles seem to reflect a difference in the immediate response to infection between these 2 groups. Nausea was equally represented in the 2 cohorts (8% vs 8.8%). Abdominal pain and diarrhea were more prevalent in the African cohort (16.7% vs 10.1% and 18.4% vs 11%, respectively). Gastrointestinal symptoms have been reported as potential mitigators and attenuators of COVID-19 disease as they generally correlated with better outcomes. Of note, conjunctivitis was highly prevalent at 64.5% in African pediatric cases compared with only 2.7% in US pediatric cases. This finding might have major consequences if not addressed adequately. It will be important to determine whether the conjunctivitis cases are of bacterial or viral origin because bacterial cases are generally treatable, whereas viral cases might linger longer and be more damaging to patients’ sight, as was reported for Ebola survivors who suffered from uveitis, even after treatment.

Another prominent symptom in our African cohort was rash, which was reported in 87.1% of patients in the Tunisian and South African cohorts. Studies from Europe have reported skin manifestations in pediatric COVID-19 patients but not at the higher prevalence as in our African cohort. Although skin rash can result from extreme immune reactions, it might also reflect potential viral-induced liver function alterations. However, we do not have any lab test results to assess liver function in our cohort.

Limitations of our study include the small cohort and low number of included countries. We did however include...
| Study/N (N = 294) | Cameroon Mekone et al, 2020 | Egypt El Kassas et al, 2020 | Ethiopia Leulseged et al, 2020 | Morocco Chalabi et al, 2020; Fakiri et al, 2020 | Nigeria Ibrahim et al, 2020; Adedeji et al, 2020 | Sierra Leone Adetola et al, 2020 | South Africa Webb et al, 2020 | Tunisia Borgi et al, 2021 |
|------------------|----------------------------|-----------------------------|-------------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Patients         | 294 (100)                  | 4 (1.36)                    | 13 (4.42)                     | 90 (30.27)                                   | 58 (19.73)                                   | 9 (3.06)                        | 23 (7.82)                      | 8 (2.72)                      |
| Collection date: March to November 2020 | Jan to Apr 2020 | Apr to May 2020 | End Jun to mid-Sep 2020 | Mar 2 to Apr 26, 2020 | Mar 25 to May 15, 2020 | Apr 24 to Sep 20, 2020 | Jun 4 to Jul 24, 2020 | Nov 1–30, 2020 |
| Male gender      | 132 (44.91)                | 1 (25)                      | 8 (61.53)                     | 33 (66.7)                                    | 41 (46.1)                                    | 31 (53.40)                      | 5 (55.6)                       | 6 (26.2)                       | 7 (85.7)                       |
| Female gender    | 162 (55.08)                | 3 (75)                      | 5 (38.47)                     | 57 (63.3)                                    | 48 (53.9)                                    | 27 (46.6)                       | 4 (44.4)                       | 17 (73.9)                      | 1 (12.5)                       |
| Age range, y     | 12 wk to 19 y              | 12 wk to 13 y               | 0-18                          | <18                                           | <19                                          | 7 days to 13 y                  | 0-18                           | <15                           | <15                           |
| Median age, y    | 11.43                      | —                           | 15                            | 8.01                                         | 12.63                                        | 5.75                           | —                             | 8                             |
| Asymptomatic     | 109 (63)                   | 2 (50)                      | 13 (100)                      | —                                             | 59 (66.33)                                   | 33 (56.9)                       | 2 (22.2)                       | —                             | —                             |
| Mild case        | 130 (52)                   | 2 (50)                      | —                             | 73 (81.1)                                    | 28 (31.45)                                   | 20 (34.5)                       | 7 (77.8)                       | —                             | —                             |
| Moderate case    | 34 (14.2)                  | —                           | —                             | 17 (18.9)                                    | 12 (13.2)                                    | 5 (8.6)                         | —                             | —                             | —                             |
| Fever            | 69 (24.6)                  | 2 (50)                      | —                             | 5 (5.6)                                       | 17 (19.09)                                   | 10 (17.3)                       | 4 (44.4)                       | 23 (100)                      | 8 (100)                       |
| Shortness of breath or dyspnea | 13 (8.5)                  | 1 (25)                      | —                             | —                                             | 12 (13.3)                                    | —                              | —                             | —                             | —                             |
| Nasal discharge  | 12 (8.1)                   | —                           | —                             | 5 (5.6)                                       | —                                             | 7 (12.0)                        | —                             | —                             | —                             |
| Cough            | 50 (20)                    | 1 (25)                      | —                             | 29 (22.2)                                    | 14 (15.68)                                   | 13 (22.5)                       | 2 (2.2)                        | —                             | —                             |
| Stuffy nose      | 2 (1.4)                    | —                           | —                             | 1 (1.35)                                      | —                                             | 1 (11.1)                        | —                             | —                             | —                             |
| Sneezing         | 10 (14.6)                  | —                           | —                             | —                                             | 9 (15.1)                                     | 1 (11.1)                        | —                             | —                             | —                             |
| Fatigue or subjective weakness | 10 (7.1)                  | —                           | —                             | 5 (5.6)                                       | —                                             | 5 (9.4)                         | —                             | —                             | —                             |
| Hypotension      | 16 (18)                    | —                           | —                             | —                                             | —                                             | 13 (56.5)                       | —                             | 3 (37.5)                      | —                             |
| Myalgia          | 53 (34.5)                  | —                           | —                             | 47 (53.3)                                     | —                                             | —                              | —                             | 6 (75)                        | —                             |
| Anosmia          | 6 (4.3)                    | —                           | —                             | 5 (5.87)                                      | 1 (1.9)                                      | —                              | —                             | —                             | —                             |
| Irritability     | 8 (6.5)                    | —                           | —                             | —                                             | 3 (5.7)                                      | —                              | —                             | 1 (12.5)                      | —                             |
| Myocardial dysfunction | 12 (14.8)                  | —                           | —                             | —                                             | —                                             | —                              | —                             | 12 (52)                       | —                             |
| Study (N = 294) | Total | Cameroon Mekone et al, 2020 | Egypt El Kassas et al, 2020 | Ethiopia Leulseged et al, 2020 | Morocco Chalabi et al, 2020; Fakiri et al, 2020 | Nigeria Ibrahim et al, 2020; Adedeji et al, 2020 | Sierra Leone Adetola et al, 2020 | South Africa Webb et al, 2020 | Tunisia Borgi et al, 2021 |
|-----------------|-------|-----------------------------|-----------------------------|--------------------------------|---------------------------------------------|----------------------------------------|----------------------------------|-------------------------------|------------------------------|
| Abdominal pain  | 29 (16.7) | —                           | —                          | —                              | 1 (1.35)                                   | 5 (9.4)                                | —                                | 15 (65.2)                     | 8 (100)                     |
| Nausea          | 13 (8)   | —                           | —                          | 4 (4.4)                        | 3 (5.7)                                    | 2 (22.2)                               | —                                | —                            | 4 (50)                     |
| Vomiting        | 7 (4.9)  | —                           | —                          | 4 (4.4)                        | —                                          | 3 (5.7)                                | —                                | —                            | —                          |
| Diarrhea        | 34 (18.4) | —                           | —                          | —                              | 6 (6.74)                                   | 5 (9.4)                                | 1 (11.1)                        | 15 (65.2)                    | 7 (87.5)                   |
| Conjunctivitis  | 20 (64.5) | —                           | —                          | —                              | —                                          | —                                      | —                                | 15 (65.2)                    | 5 (62.5)                   |
| Headache        | 21 (8.1) | —                           | —                          | 9 (10)                         | —                                          | —                                      | 2 (22.2)                        | —                            | 6 (75)                     |
| Sore throat     | 37 (15)  | —                           | —                          | 20 (22.2)                      | 1 (1.35)                                   | 12 (20)                                | —                                | —                            | 4 (50)                     |
| Rash            | 27 (87.1)| —                           | —                          | 20 (22.2)                      | 1 (1.35)                                   | 12 (20)                                | —                                | 20 (87)                      | 7 (87.5)                   |
| Lymphocytopenia | 8 (5.2)  | —                           | —                          | —                              | 7 (8)                                      | —                                      | 1 (11.1)                        | —                            | —                          |
| Lymphocytosis   | 23 (15.8)| —                           | —                          | —                              | 23 (40)                                    | —                                      | —                                | —                            | —                          |

Values are n (%) unless otherwise defined.

aThe studies listed here can be found in Supplementary Table 1.
all published reports. Reports from different countries do not have the same set of data, some being more comprehensive than others. Prospective studies need to include standardized protocols developed by the World Health Organization, especially for pandemic diseases.

In conclusion, this is the first African pediatric COVID-19 meta-analysis to show that African pediatric COVID-19 has a distinguishable profile with more pronounced gastrointestinal symptoms such as diarrhea and abdominal pain that likely attenuate the disease severity. Conjunctivitis and skin rash were prominently present in our cohort and deserve more attention and follow-up. Cough, fever, and shortness of breath were less prevalent in our cohort. As a sign of resilience in pediatric African patients, the level of asymptomatic cases was notable compared with other continents.

Supplementary Material
Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org and at https://doi.org/10.1053/j.gastro.2021.08.020.

ANAS BRIM
YUSUF ASHKTORAB
TIZIANO RUSSO
Department of Pathology
Cancer Center
Howard University
Washington, DC

ANTONIO PIZUORNO
Faculty of Medicine
School of Medicine
La Universidad del Zulia
Maracaibo, Zulia state, Venezuela

GHOLAMREZA OSKROCHI
College of Engineering and Technology
American University of the Middle East
Kuwait

HAZZAN BRIM
Department of Pathology
Cancer Center
Howard University
Washington, DC

References
1. King JA, et al. CMAJ 2021;193:E1–E9.
2. Salman S, et al. Med Hypotheses 2020;140:1–2.
3. Schouten LR, et al. Ann Intensive Care 2019;9:55.
4. Ashktorab Y, et al. Gastroenterology 2021;160:1842–1844.
5. Yeh S, et al. Ocul Immunol Inflamm 2018;26:1128–1134.
6. Andina D, et al. Clin Exp Dermatol 2021;46:462–472.
7. Bergasa NV. Semin Cutan Med Surg 2011;30:93–98.
8. Rentsch CT, et al. PLoS Med 2020;17:e1003379.

Received June 7, 2021. Accepted August 13, 2021.

Correspondence
Address correspondence to: Hassan Brim, PhD, Howard University College of Medicine, 2041 Georgia Avenue, NW, Washington, DC 20060. e-mail: hbrim@howard.edu.

CRediT Authorship Contributions
Anas Brim, HS (Data curation: Equal; Methodology: Equal; Writing – review & editing: Supporting). Yusuf Ashktorab, HS (Data curation: Equal; Methodology: Equal; Writing – review & editing: Supporting). Tiziano Russo, AS (Data curation: Equal; Methodology: Equal; Writing – review & editing: Supporting). Antonio Pizuorno, MD (Data curation: Lead; Formal analysis: Lead; Writing – review & editing: Supporting). Hassan Brim, PhD (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Investigation: Lead; Methodology: Lead; Project administration: Lead; Resources: Lead; Supervision: Lead; Writing – original draft: Lead; Writing – review & editing: Lead).

Conflicts of interest
The authors disclose no conflicts.

Funding
This project was supported in part by the National Institute on Minority Health and Health Disparities of the National Institutes of Health under Award Number G12MD007597. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Supplemental Figure 1. Gender (A) and age (B) distribution of the study patients.
Supplemental Figure 2. Heatmaps showing the prevalence of abdominal pain (A), diarrhea (B), and asymptomatic patients (C) in selected studies from different African countries.
**Supplementary Table 1.** References and Included Countries for This Study

| Study (N = 294) | Cameroon | Egypt | Ethiopia | Morocco | Nigeria | Sierra Leone | South Africa | Tunisia |
|----------------|----------|-------|----------|---------|---------|--------------|--------------|---------|
|                | Mekone et al, 2020 | El Kassas et al, 2020 | Leulseged et al, 2020 | Chalabi et al, 2020; Fakiri et al, 2020 | Ibrahim et al, 2020; Adedeji et al, 2020 | Adetola et al, 2020 | Webb et al, 2020 | Borgi et al, 2021 |

**References**

1. Mekone I, et al. Open J Pediatr 2020;10:363–368.
2. El Kassas M, et al. J Infect Dev Countr 2020;14:1352–1360.
3. Leulseged TW, et al. medRxiv 2021;16:e0246087.
4. Fakiri KE, et al. Indian Pediatr 2020;57:808–810.
5. Chekhlabi N, et al. Pan Afr Med J 2020;35(Suppl 2):57.
6. Ibrahim OR, et al. Pan Afr Med J 2020;35:53.
7. Adedeji IA, et al. Pan Afr Med J 2020;35:145.
8. Adetola HH, et al. Pan Afr Med J 2020;37:28.
9. Webb K, et al. Lancet Child Adolesc Health 2020;4:e38.
10. Borgi A, et al. Mediterr J Hematol Infect Dis 2021;13:e2021023.